DNA Methylation in Ovarian and Endometrial Cancers: Predictive and Mechanistic Roles in PARP Inhibitor and ICI Response
Cancer Science · 2025
DOI: 10.1111/cas.70189 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancer Science, 2025. Verfasst von Shuhei Kitamura und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, The University of Tokyo, Tokyo, Japan. Hauptthemen laut MEDLINE: DNA Methylation, Poly(ADP-ribose) Polymerase Inhibitors, Endometrial Neoplasms, Immune Checkpoint Inhibitors. Die Arbeit nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Japan Society for the Promotion of Science, Japan Agency for Medical Research and Development.
Abstract (Originalsprache)
Cancer treatment is shifting from an organ‐based approach to one driven by biological phenotypes, emphasizing the need to understand molecular mechanisms. DNA methylation plays a pivotal role in tumor biology, not only through gene silencing but also by inducing distinct behaviors beyond genetic mutations. In gynecologic cancers, molecular diagnostics, such as homologous recombination deficiency status guiding poly(ADP‐ribose) polymerase (PARP) inhibitor therapy in ovarian cancer and deficient mismatch repair/microsatellite instability‐high status informing immune checkpoint inhibitor (ICI) therapy in endometrial cancer have already been used in clinical practice. However, tumors with epigenetically driven functional deficiencies, such as BRCA1 promoter methylation in homologous recombination‐deficient ovarian cancers or MLH1 promoter methylation in deficient mismatch repair/microsatellite instability‐high endometrial cancers, often exhibit poorer prognoses and reduced therapeutic responses compared to their genetically mutated counterparts. Given the unique impact of DNA methylation, precise detection is crucial. Integrating methylation analysis into molecular classification could refine diagnostics—both by identifying mechanistic contributors to treatment response and by serving as predictive biomarkers for therapy selection—thereby optimizing patient management. This review explores the role of DNA methylation in modulating responses to PARP inhibitors and ICIs, highlights its promise as a biomarker in precision oncology, and outlines current developments and clinical challenges in BRCA1 and MLH1 methylation assays.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Obstetrics and Gynecology, The University of Tokyo, Tokyo, Japan.
- Chiba Cancer Center, Research Institute, Division of Cell Therapy, Chiba, Japan.
- Department of Clinical Genomics, The University of Tokyo, Tokyo, Japan.
ORCID-Profile: Ayumi Taguchi, Kenbun Sone, Katsutoshi Oda
Förderung
- Japan Society for the Promotion of Science
- Japan Agency for Medical Research and Development
Zitieren
APA
Kitamura, S., Taguchi, A., Tamai, K., Yamamoto, Y., Duong, A. Q., Yoshimoto, D., Mori, A., Ishizaka, A., Tsuchimochi, S., Sone, K., Kawazu, M., Oda, K., & Hirota, Y. (2025). DNA Methylation in Ovarian and Endometrial Cancers: Predictive and Mechanistic Roles in PARP Inhibitor and ICI Response. Cancer Science. https://doi.org/10.1111/cas.70189
Vancouver
Kitamura S, Taguchi A, Tamai K, Yamamoto Y, Duong AQ, Yoshimoto D, et al. DNA Methylation in Ovarian and Endometrial Cancers: Predictive and Mechanistic Roles in PARP Inhibitor and ICI Response. Cancer Science. 2025. doi:10.1111/cas.70189
BibTeX
@article{Kitamura2025,
author = {Kitamura, Shuhei and Taguchi, Ayumi and Tamai, Kana and Yamamoto, Yoko and Duong, Anh Quynh and Yoshimoto, Daisuke and Mori, Ayako and Ishizaka, Aya and Tsuchimochi, Saki and Sone, Kenbun and Kawazu, Masahito and Oda, Katsutoshi and Hirota, Yasushi},
title = {DNA Methylation in Ovarian and Endometrial Cancers: Predictive and Mechanistic Roles in PARP Inhibitor and ICI Response},
journal = {Cancer Science},
year = {2025},
doi = {10.1111/cas.70189}
}
EUVIMED